In this same cohort, tissue samples with high RIPK3 expression show strong reactivity to anti-CD8 and anti-Granzyme B antibodies (Fig. S8E), implicating the involvement of RIPK3 in regulating the anti-tumor microenvironment. Here, CD8A is linked to neoplasm.